Sfoglia per Autore
Reply to Y. Pointreau et al
2012-01-01 Tronconi, Mc; Sclafani, F; Rimassa, L; Carnaghi, C; Personeni, N; Santoro, A
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma
2013-01-01 Rimassa, L; Pressiani, T; Boni, C; Carnaghi, C; Rota Caremoli, E; Fagiuoli, S; Foa, P; Salvagni, S; Cortesi, E; Tronconi, Mc; Personeni, N; Bozzarelli, S; Banzi, Mc; Fanello, S; Lutman, Fr; Giordano, L; Santoro, A
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomized, placebo-controlled phase 2 study.
2013-01-01 Santoro, A; Rimassa, L; Borbath, I; Daniele, B; Salvagni, S; Van Laethem, J L; Van Vlierberghe, H; Trojan, J; Kolligs, F T; Weiss, A; Miles, S; Gasbarrini, A; Lencioni, M; Cicalese, L; Sherman, M; Gridelli, C; Buggisch, P; Gerken, G; Schmid, R M; Boni, C; Personeni, N; Hassoun, Z; Abbadessa, G; Schwartz, B; Von Roemeling, R; Lamar, M E; Chen, Y; Porta, C
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer
2013-01-01 Sclafani, F; Incarbone, M; Rimassa, L; Personeni, N; Giordano, L; Alloisio, M; Santoro, A
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma
2013-01-01 Rimassa, L; Personeni, N; Simonelli, M; Santoro, A
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma
2013-01-01 Personeni, N; Rimassa, L; Pressiani, T; Destro, A; Ligorio, C; Tronconi, Mc; Bozzarelli, S; Carnaghi, C; Di Tommaso, L; Giordano, L; Roncalli, M; Santoro, A
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach
2014-01-01 Comito, T; Cozzi, L; Clerici, E; Campisi, Mc; Liardo, Rle; Navarria, P; Ascolese, A; Tozzi, A; Iftode, C; De Rose, F; Villa, E; Personeni, N; Rimassa, L; Santoro, A; Fogliata, A; Mancosu, P; Tomatis, S; Scorsetti, M
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study
2015-01-01 Santoro, A; Gebbia, V; Pressiani, T; Testa, A; Personeni, N; Bajardi, Ea; Foa, P; Buonadonna, A; Bencardino, K; Barone, C; Ferrari, D; Zaniboni, A; Tronconi, Mc; Carteni, G; Milella, M; Comandone, A; Ferrari, S; Rimassa, L
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study
2015-01-01 Personeni, N; Rimassa, L; Verusio, C; Barni, S; Rubino, L; Bozzarelli, S; Villa, E; Carnaghi, C; Tronconi, Mc; Gerardi, C; Galli, F; Floriani, I; Destro, A; Raschioni, C; Labianca, R; Santoro, A
Tivantinib for hepatocellular carcinoma
2015-01-01 Rimassa, L; Personeni, N; Santoro, A
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma
2015-01-01 Lopci, E; Torzilli, G; Poretti, D; de Neto, Ljs; Donadon, M; Rimassa, L; Lanza, E; Sabongi, Jg; Ceriani, R; Personeni, N; Palmisano, A; Pedicini, V; Comito, T; Scorsetti, M; Chiti, A
KRAS mutation in lung metastases from colorectal cancer : Prognostic implications
2016-01-01 Ghidini, M.; Personeni, N.; Bozzarelli, S.; Baretti, M.; Basso, G.; Bianchi, P.; Tronconi, M. C.; Pressiani, T.; Grizzi, F.; Giordano, L.; Malesci, A.; Alloisio, M.; Laghi, L.; Santoro, A.; Rimassa, L.
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications
2016-01-01 Personeni, N; Baretti, M; Bozzarelli, S; Spaggiari, P; Rubino, L; Tronconi, Mc; Fumagalli, U; Rosati, R; Giordano, L; Roncalli, M; Santoro, A; Rimassa, L
The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients
2016-01-01 Destro, A; Lo Russo, C; Spaggiari, P; Armenia, S; Bellofiore, E; Lorini, M; Brambilla, T; Cimino, Mm; Spinelli, A; Personeni, N; Rimassa, L; Di Tommaso, L; Roncalli, M; DI TOMMASO, Luca
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib
2016-01-01 Rimassa, L; Abbadessa, G; Personeni, N; Porta, C; Borbath, I; Daniele, B; Salvagni, S; Van Laethem, Jl; Van Vlierberghe, H; Trojan, J; De Toni, En; Weiss, A; Miles, S; Gasbarrini, A; Lencioni, M; Lamar, Me; Wang, Y; Shuster, D; Schwartz, Be; Santoro, A
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study
2016-01-01 Comito, T; Cozzi, L; Clerici, E; Franzese, C; Tozzi, A; Iftode, C; Navarria, P; D’Agostino, G; Rimassa, L; Carnaghi, C; Personeni, N; Tronconi, Mc; De Rose, F; Franceschini, D; Ascolese, Am; Fogliata, A; Tomatis, S; Santoro, A; Zerbi, A; Scorsetti, M
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA)
2016-01-01 Mazzaferro, V. M.; Shaib, W.; Rimassa, L.; Harris, W.; Personeni, N.; El-rayes, B.; Tolcher, A.; Hall, T.; Wang, Y.; Schwartz, B.; Kazakin, J.; Michele, DROZ DIT BUSSET; Cotsoglou, C.; Papadopoulos, K.
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study
2017-01-01 Personeni, N; Giordano, L; Abbadessa, G; Porta, C; Borbath, I; Daniele, B; Salvagni, S; Van Laethem, Jl; Van Vlierberghe, H; Trojan, J; De Toni, En; Weiss, A; Miles, S; Gasbarrini, A; Lencioni, M; Lamar, Me; Wang, Y; Shuster, D; Schwartz, B; Santoro, A; Rimassa, L
Regorafenib for the treatment of unresectable hepatocellular carcinoma
2017-01-01 Rimassa, L; Pressiani, T; Personeni, N; Santoro, A
Sorafenib in hepatitis C-virus negative patients with hepatocellular carcinoma: don’t throw the baby out with the bathwater
2017-01-01 Personeni, N; Rimassa, L; Giordano, L; Santoro, A
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Reply to Y. Pointreau et al | 1-gen-2012 | Tronconi, Mc; Sclafani, F; Rimassa, L; Carnaghi, C; Personeni, N; Santoro, A | |
| A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma | 1-gen-2013 | Rimassa, L; Pressiani, T; Boni, C; Carnaghi, C; Rota Caremoli, E; Fagiuoli, S; Foa, P; Salvagni, S; Cortesi, E; Tronconi, Mc; Personeni, N; Bozzarelli, S; Banzi, Mc; Fanello, S; Lutman, Fr; Giordano, L; Santoro, A | |
| Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomized, placebo-controlled phase 2 study. | 1-gen-2013 | Santoro, A; Rimassa, L; Borbath, I; Daniele, B; Salvagni, S; Van Laethem, J L; Van Vlierberghe, H; Trojan, J; Kolligs, F T; Weiss, A; Miles, S; Gasbarrini, A; Lencioni, M; Cicalese, L; Sherman, M; Gridelli, C; Buggisch, P; Gerken, G; Schmid, R M; Boni, C; Personeni, N; Hassoun, Z; Abbadessa, G; Schwartz, B; Von Roemeling, R; Lamar, M E; Chen, Y; Porta, C | |
| The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer | 1-gen-2013 | Sclafani, F; Incarbone, M; Rimassa, L; Personeni, N; Giordano, L; Alloisio, M; Santoro, A | |
| Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma | 1-gen-2013 | Rimassa, L; Personeni, N; Simonelli, M; Santoro, A | |
| Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma | 1-gen-2013 | Personeni, N; Rimassa, L; Pressiani, T; Destro, A; Ligorio, C; Tronconi, Mc; Bozzarelli, S; Carnaghi, C; Di Tommaso, L; Giordano, L; Roncalli, M; Santoro, A | |
| Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach | 1-gen-2014 | Comito, T; Cozzi, L; Clerici, E; Campisi, Mc; Liardo, Rle; Navarria, P; Ascolese, A; Tozzi, A; Iftode, C; De Rose, F; Villa, E; Personeni, N; Rimassa, L; Santoro, A; Fogliata, A; Mancosu, P; Tomatis, S; Scorsetti, M | |
| A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study | 1-gen-2015 | Santoro, A; Gebbia, V; Pressiani, T; Testa, A; Personeni, N; Bajardi, Ea; Foa, P; Buonadonna, A; Bencardino, K; Barone, C; Ferrari, D; Zaniboni, A; Tronconi, Mc; Carteni, G; Milella, M; Comandone, A; Ferrari, S; Rimassa, L | |
| FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study | 1-gen-2015 | Personeni, N; Rimassa, L; Verusio, C; Barni, S; Rubino, L; Bozzarelli, S; Villa, E; Carnaghi, C; Tronconi, Mc; Gerardi, C; Galli, F; Floriani, I; Destro, A; Raschioni, C; Labianca, R; Santoro, A | |
| Tivantinib for hepatocellular carcinoma | 1-gen-2015 | Rimassa, L; Personeni, N; Santoro, A | |
| Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma | 1-gen-2015 | Lopci, E; Torzilli, G; Poretti, D; de Neto, Ljs; Donadon, M; Rimassa, L; Lanza, E; Sabongi, Jg; Ceriani, R; Personeni, N; Palmisano, A; Pedicini, V; Comito, T; Scorsetti, M; Chiti, A | |
| KRAS mutation in lung metastases from colorectal cancer : Prognostic implications | 1-gen-2016 | Ghidini, M.; Personeni, N.; Bozzarelli, S.; Baretti, M.; Basso, G.; Bianchi, P.; Tronconi, M. C.; Pressiani, T.; Grizzi, F.; Giordano, L.; Malesci, A.; Alloisio, M.; Laghi, L.; Santoro, A.; Rimassa, L. | |
| Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications | 1-gen-2016 | Personeni, N; Baretti, M; Bozzarelli, S; Spaggiari, P; Rubino, L; Tronconi, Mc; Fumagalli, U; Rosati, R; Giordano, L; Roncalli, M; Santoro, A; Rimassa, L | |
| The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients | 1-gen-2016 | Destro, A; Lo Russo, C; Spaggiari, P; Armenia, S; Bellofiore, E; Lorini, M; Brambilla, T; Cimino, Mm; Spinelli, A; Personeni, N; Rimassa, L; Di Tommaso, L; Roncalli, M; DI TOMMASO, Luca | |
| Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib | 1-gen-2016 | Rimassa, L; Abbadessa, G; Personeni, N; Porta, C; Borbath, I; Daniele, B; Salvagni, S; Van Laethem, Jl; Van Vlierberghe, H; Trojan, J; De Toni, En; Weiss, A; Miles, S; Gasbarrini, A; Lencioni, M; Lamar, Me; Wang, Y; Shuster, D; Schwartz, Be; Santoro, A | |
| Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study | 1-gen-2016 | Comito, T; Cozzi, L; Clerici, E; Franzese, C; Tozzi, A; Iftode, C; Navarria, P; D’Agostino, G; Rimassa, L; Carnaghi, C; Personeni, N; Tronconi, Mc; De Rose, F; Franceschini, D; Ascolese, Am; Fogliata, A; Tomatis, S; Santoro, A; Zerbi, A; Scorsetti, M | |
| ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) | 1-gen-2016 | Mazzaferro, V. M.; Shaib, W.; Rimassa, L.; Harris, W.; Personeni, N.; El-rayes, B.; Tolcher, A.; Hall, T.; Wang, Y.; Schwartz, B.; Kazakin, J.; Michele, DROZ DIT BUSSET; Cotsoglou, C.; Papadopoulos, K. | |
| Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study | 1-gen-2017 | Personeni, N; Giordano, L; Abbadessa, G; Porta, C; Borbath, I; Daniele, B; Salvagni, S; Van Laethem, Jl; Van Vlierberghe, H; Trojan, J; De Toni, En; Weiss, A; Miles, S; Gasbarrini, A; Lencioni, M; Lamar, Me; Wang, Y; Shuster, D; Schwartz, B; Santoro, A; Rimassa, L | |
| Regorafenib for the treatment of unresectable hepatocellular carcinoma | 1-gen-2017 | Rimassa, L; Pressiani, T; Personeni, N; Santoro, A | |
| Sorafenib in hepatitis C-virus negative patients with hepatocellular carcinoma: don’t throw the baby out with the bathwater | 1-gen-2017 | Personeni, N; Rimassa, L; Giordano, L; Santoro, A |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile